Close Menu

Derek Lowe comments on the news that Pfizer's (now discontinued) inhaled insulin (Exubera) had led to an increased chance of lung cancer in clinical trials. Considering the difficulties and risks of drug development, it's hard to guarantee outcome of clinical trials, especially when they should take into account that disease often happens on the order of years, not months. "The truth, as far as I can see, is that no one can guarantee the safety of a new drug.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

A survey by Nature finds that most researchers want scientific meetings to continue virtually or with a virtual component, even after the pandemic ends.

Bloomberg reports that the B.1.351 SARS-CoV-2 viral variant could prompt the formulation of better vaccines.

Certain blood proteins may be able to distinguish COVID-19 patients who will become critically ill from those who will not, the Atlanta Journal-Constitution reports.

In Genome Biology this week: algorithm to assess regulatory features, approach to integrate multiple single-cell RNA-seq datasets, and more.